Insiders who reported open-market trades in the last 12 months at the companies Michael Aaron Kelly files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Greg D. Aunan - $321K in NEO purchases and sales in the last 12 months
Alicia C. Olivo - $300K in NEO purchases and sales in the last 12 months
Warren Stone - $277K in NEO purchases and sales in the last 12 months
Lynn A. Tetrault - $119K in NEO purchases and sales in the last 12 months
James Schladen - $111K in BOOM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Michael Aaron Kelly is a corporate insider, tracked as Director of Prime Medicine, Inc. (PRME). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Michael Aaron Kelly last file a Form 4?
The most recent primary Form 4 on record is dated 8 June 2026, one of 8 filings going back to 2025.
Has Michael Aaron Kelly been buying or selling stock?
Recorded transactions: 1 open-market purchase ($38K) and 0 open-market sales across all tracked filings.
Michael Aaron Kelly is Director of Prime Medicine, Inc. (PRME). 8 SEC Form 4 filings on record going back to 2025, most recently on 8 June 2026. Most recent open-market trade: bought $38K of NEO on 28 May 2025. Lifetime open-market purchases: $38K.
Recent transactions
6
The latest 6 SEC Form 4 transactions reported by Michael Aaron Kelly.
InsiderAlpha's records for Michael Aaron Kelly go back to 2025: 8 primary Form 4 filings, an average of 4.0 per year. The typical open-market purchase is $38K (1 buy totaling $38K). The largest single buy on record is $38K of NEO in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
